We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Revolutionary AI Tool Transforms Disease Visualization

By LabMedica International staff writers
Posted on 10 Feb 2025

Genes serve as the body's blueprint, while proteins execute the instructions within those blueprints to maintain cell function. More...

Occasionally, alterations in these instructions—known as mutations—can interfere with this process and cause disease. Omics refers to the study of genes, proteins, and other molecular data to explore the body's functions and how diseases evolve. Now, an artificial intelligence (AI) tool is assisting in converting vast, complex biological data into two-dimensional circular visuals. By mapping this data, the tool might offer clinicians and researchers a novel method for visualizing disease patterns, such as those found in cancer and neurological disorders, which could aid in directing personalized treatments. Additionally, it may provide an intuitive means of exploring disease mechanisms and interactions.

Developed by researchers at Mayo Clinic (Rochester, MN, USA), the tool called OmicsFootPrint helps to clarify these complexities by transforming data—such as gene activity, mutations, and protein levels—into vibrant, circular maps that offer a clearer understanding of what’s occurring within the body. In their study, the researchers employed OmicsFootPrint to examine drug responses and cancer multi-omics data. The tool successfully distinguished between two types of breast cancer—lobular and ductal carcinomas—with an average accuracy of 87%. In lung cancer, it showed over 95% accuracy in identifying two types: adenocarcinoma and squamous cell carcinoma. The findings, published in Nucleic Acids Research, revealed that combining various types of molecular data yields more accurate results than using just a single type.

The OmicsFootPrint also demonstrates promise in generating meaningful insights even with limited datasets. It utilizes advanced AI techniques that learn from existing data and apply this knowledge to new situations, a process known as transfer learning. For instance, it assisted researchers in achieving over 95% accuracy in identifying lung cancer subtypes with less than 20% of the usual data volume. To further enhance its accuracy and insights, the OmicsFootPrint framework incorporates a sophisticated method called SHAP (SHapley Additive exPlanations). SHAP highlights the key markers, genes, or proteins that impact the results, aiding researchers in understanding the underlying factors driving disease patterns. In addition to research, OmicsFootPrint is also intended for clinical use. It compresses large biological datasets into compact images that occupy only 2% of the original storage space. This compression could simplify the integration of the images into electronic medical records, potentially guiding future patient care. The research team is working on expanding OmicsFootPrint to explore additional diseases, including neurological conditions and other complex disorders. They are also focusing on updates to enhance the tool's accuracy and flexibility, such as the ability to identify new disease markers and drug targets.

"Data becomes most powerful when you can see the story it's telling," says Krishna Rani Kalari, Ph.D., lead author of the study and associate professor of biomedical informatics at Mayo Clinic's Center for Individualized Medicine. "The OmicsFootPrint could open doors to discoveries we haven't been able to achieve before."


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Urine Analyzer
respons® UDS100
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.